Department of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gröna Stråket 8, SE-413 45, Gothenburg, Sweden.
Department of Plastic and Reconstructive Surgery, Region Västra Götaland, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45, Gothenburg, Sweden.
BMC Surg. 2021 Sep 11;21(1):343. doi: 10.1186/s12893-021-01336-7.
There is no consensus for when publicly funded breast reduction is indicated and recommendations in guidelines vary greatly, indicating a lack of evidence and unequal access. The primary aim of this review was to examine risks and benefits of breast reduction to treat breast hypertrophy. Secondary aims were to examine how the studies defined breast hypertrophy and indications for a breast reduction.
A systematic literature search was conducted in PubMed, MEDLINE All, Embase, the Cochrane Library, and PsycInfo. The included articles were critically appraised, and certainty of evidence was assessed using the GRADE approach. Meta-analyses were performed when possible.
Fifteen articles were included; eight reporting findings from four randomised controlled trials, three non-randomised controlled studies, three case series, and one qualitative study. Most studies had serious study limitations and problems with directness. Few of the studies defined breast hypertrophy. The studies showed significantly improved health-related quality of life and sexuality-related outcomes in patients who had undergone breast reduction compared with controls, as well as reduced depressive symptoms, levels of anxiety and pain. Most effect sizes exceeded the reported minimal important difference for the scale. Certainty of evidence for the outcomes above is low (GRADE ⊕ ⊕). Although four studies reported significantly improved physical function, the effect is uncertain (very low certainty of evidence, GRADE ⊕). None of the included studies reported data regarding work ability or sick leave. Three case series reported a 30-day mortality of zero. Reported major complications after breast reduction ranged from 2.4 to 14% and minor complications from 2.4 to 69%.
There is a lack of high-quality studies evaluating the results of breast reduction. A breast reduction may have positive psychological and physical effects for women, but it is unclear which women benefit the most and which women should be offered a breast reduction in the public healthcare system. Several priorities for further research have been identified.
PRE-REGISTRATION: The study is based on a Health Technology Assessment report, pre-registered and then published on the website of The Regional HTA Centre of Region Västra Götaland, Sweden.
目前对于公共资金资助乳房缩小术的适应证尚无共识,指南中的建议差异很大,这表明缺乏证据且存在机会不平等。本研究的主要目的是评估乳房缩小术治疗乳房肥大的风险和获益。次要目的是评估研究如何定义乳房肥大和乳房缩小术的适应证。
对 PubMed、MEDLINE All、Embase、Cochrane 图书馆和 PsycInfo 进行系统文献检索。对纳入的文章进行批判性评估,并使用 GRADE 方法评估证据确定性。当可能时进行荟萃分析。
纳入 15 篇文章,其中 8 篇报告了 4 项随机对照试验、3 项非随机对照研究、3 项病例系列研究和 1 项定性研究的结果。大多数研究存在严重的研究局限性和直接性问题。很少有研究定义了乳房肥大。与对照组相比,乳房缩小术患者的健康相关生活质量和与性相关的结局显著改善,抑郁症状、焦虑水平和疼痛减轻。大多数效应量超过了量表报告的最小重要差异。上述结局的证据确定性为低(GRADE⊕⊕)。尽管 4 项研究报告了身体功能显著改善,但效果不确定(证据确定性极低,GRADE⊕)。纳入的研究均未报告关于工作能力或病假的数据。3 项病例系列研究报告的 30 天死亡率为零。乳房缩小术后报告的主要并发症发生率为 2.4%至 14%,次要并发症发生率为 2.4%至 69%。
目前缺乏评估乳房缩小术结果的高质量研究。乳房缩小术可能对女性产生积极的心理和生理影响,但尚不清楚哪些女性受益最大,以及哪些女性应在公共医疗体系中获得乳房缩小术。已经确定了一些进一步研究的优先事项。
该研究基于一项卫生技术评估报告,在瑞典西约塔兰地区卫生技术评估中心的网站上进行了预注册,然后发表。